|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar
|
|
2
|
Zhu YH, Fu L, Chen L, Qin YR, Liu H, Xie
F, Zeng T, Dong SS, Li J, Li Y, et al: Downregulation of the novel
tumor suppressor DIRAS1 predicts poor prognosis in esophageal
squamous cell carcinoma. Cancer Res. 73:2298–2309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl
8): S4–S66. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsai ST, Wang PJ, Liou NJ, Lin PS, Chen CH
and Chang WC: ICAM1 is a potential cancer stem cell marker of
esophageal squamous cell carcinoma. PLoS One. 10:e01428342015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimada H, Shiratori T, Okazumi S,
Matsubara H, Nabeya Y, Shuto K, Akutsu Y, Hayashi H, Isono K and
Ochiai T: Have surgical outcomes of pathologic T4 esophageal
squamous cell carcinoma really improved? Analysis of 268 cases
during 45 years of experience. J Am Coll Surg. 206:48–56. 2008.
View Article : Google Scholar
|
|
7
|
Radisky ES and Radisky DC: Matrix
metalloproteinase-induced epithelial-mesenchymal transition in
breast cancer. J Mammary Gland Biol Neoplasia. 15:201–212. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pisani P, Parkin DM, Bray F and Ferlay J:
Estimates of the worldwide mortality from 25 cancers in 1990. Int J
Cancer. 83:18–29. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Primakoff P and Myles DG: The ADAM gene
family: surface proteins with adhesion and protease activity.
Trends Genet. 16:83–87. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Duffy MJ, Mullooly M, ODonovan N, Sukor S,
Crown J, Pierce A and McGowan PM: The ADAMs family of proteases:
new biomarkers and therapeutic targets for cancer? Clin Proteomics.
8:92011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wolfsberg TG, Primakoff P, Myles DG and
White JM: ADAM, a novel family of membrane proteins containing a
disintegrin and metalloprotease domain: multipotential functions in
cell-cell and cell-matrix interactions. J Cell Biol. 131:275–278.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Walker JL, Fournier AK and Assoian RK:
Regulation of growth factor signaling and cell cycle progression by
cell adhesion and adhesion-dependent changes in cellular tension.
Cytokine Growth Factor Rev. 16:395–405. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mazzocca A, Coppari R, De Franco R, Cho
JY, Libermann TA, Pinzani M and Toker A: A secreted form of ADAM9
promotes carcinoma invasion through tumor-stromal interactions.
Cancer Res. 65:4728–4738. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mochizuki S and Okada Y: ADAMs in cancer
cell proliferation and progression. Cancer Sci. 98:621–628. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Klein T and Bischoff R: Active
metalloproteases of the a disintegrin and metalloprotease (ADAM)
family: biological function and structure. J Proteome Res.
10:17–33. 2011. View Article : Google Scholar
|
|
16
|
Lu X, Lu D, Scully M and Kakkar V: ADAM
proteins - therapeutic potential in cancer. Curr Cancer Drug
Targets. 8:720–732. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hartmann D, de Strooper B, Serneels L,
Craessaerts K, Herreman A, Annaert W, Umans L, Lübke T, Lena Illert
A, von Figura K, et al: The disintegrin/metalloprotease ADAM 10 is
essential for Notch signalling but not for alpha-secretase activity
in fibroblasts. Hum Mol Genet. 11:2615–2624. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lendeckel U, Kohl J, Arndt M, Carl-McGrath
S, Donat H and Röcken C: Increased expression of ADAM family
members in human breast cancer and breast cancer cell lines. J
Cancer Res Clin Oncol. 131:41–48. 2005. View Article : Google Scholar
|
|
19
|
Guo J, He L, Yuan P, Wang P, Lu Y, Tong F,
Wang Y, Yin Y, Tian J and Sun J: ADAM10 overexpression in human
non-small cell lung cancer correlates with cell migration and
invasion through the activation of the Notch1 signaling pathway.
Oncol Rep. 28:1709–1718. 2012.PubMed/NCBI
|
|
20
|
You B, Shan Y, Shi S, Li X and You Y:
Effects of ADAM10 upregulation on progression, migration, and
prognosis of naso-pharyngeal carcinoma. Cancer Sci. 106:1506–1514.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jones AV, Lambert DW, Speight PM and
Whawell SA: ADAM 10 is over expressed in oral squamous cell
carcinoma and contributes to invasive behaviour through a
functional association with αvβ6 integrin. FEBS Lett.
587:3529–3534. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW
and Liu TY: Increase of disintergin metalloprotease 10 (ADAM10)
expression in oral squamous cell carcinoma. Cancer Lett. 245:33–43.
2007. View Article : Google Scholar
|
|
23
|
Shao Y, Sha XY, Bai YX, Quan F and Wu SL:
Effect of a disintegrin and metalloproteinase 10 gene silencing on
the proliferation, invasion and migration of the human tongue
squamous cell carcinoma cell line TCA8113. Mol Med Rep. 11:212–218.
2015.
|
|
24
|
Yue Y, Shao Y, Luo Q, Shi L and Wang Z:
Downregulation of ADAM10 expression inhibits metastasis and
invasiveness of human hepatocellular carcinoma HepG2 cells. BioMed
Res Int. 2013:4345612013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang W, Liu S, Liu K, Wang Y, Ji B, Zhang
X and Liu Y: A disintegrin and metalloprotease (ADAM)10 is highly
expressed in hepatocellular carcinoma and is associated with tumour
progression. J Int Med Res. 42:611–618. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and
Tao HQ: ADAM 10 is associated with gastric cancer progression and
prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gavert N, Sheffer M, Raveh S, Spaderna S,
Shtutman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, et
al: Expression of L1-CAM and ADAM10 in human colon cancer cells
induces metastasis. Cancer Res. 67:7703–7712. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gaida MM, Haag N, Günther F, Tschaharganeh
DF, Schirmacher P, Friess H, Giese NA, Schmidt J and Wente MN:
Expression of a disintegrin and metalloprotease 10 in pancreatic
carcinoma. Int J Mol Med. 26:281–288. 2010.PubMed/NCBI
|
|
29
|
Fu L, Liu N, Han Y, Xie C, Li Q and Wang
E: ADAM10 regulates proliferation, invasion, and chemoresistance of
bladder cancer cells. Tumour Biol. 35:9263–9268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Doberstein K, Pfeilschifter J and Gutwein
P: The transcription factor PAX2 regulates ADAM10 expression in
renal cell carcinoma. Carcinogenesis. 32:1713–1723. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Turner SL, Blair-Zajdel ME and Bunning RA:
ADAMs and ADAMTSs in cancer. Br J Biomed Sci. 66:117–128.
2009.PubMed/NCBI
|
|
32
|
Woods N, Trevino J, Coppola D, Chellappan
S, Yang S and Padmanabhan J: Fendiline inhibits proliferation and
invasion of pancreatic cancer cells by interfering with ADAM10
activation and β-catenin signaling. Oncotarget. 6:35931–35948.
2015.PubMed/NCBI
|
|
33
|
Maretzky T, Reiss K, Ludwig A, Buchholz J,
Scholz F, Proksch E, de Strooper B, Hartmann D and Saftig P: ADAM10
mediates E-cadherin shedding and regulates epithelial cell-cell
adhesion, migration, and beta-catenin translocation. Proc Natl Acad
Sci USA. 102:9182–9187. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dittmer A, Hohlfeld K, Lützkendorf J,
Müller LP and Dittmer J: Human mesenchymal stem cells induce
E-cadherin degradation in breast carcinoma spheroids by activating
ADAM10. Cell Mol Life Sci. 66:3053–3065. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee SB, Schramme A, Doberstein K, Dummer
R, Abdel-Bakky MS, Keller S, Altevogt P, Oh ST, Reichrath J, Oxmann
D, et al: ADAM10 is upregulated in melanoma metastasis compared
with primary melanoma. J Invest Dermatol. 130:763–773. 2010.
View Article : Google Scholar
|
|
36
|
Bánkfalvi A, Krassort M, Buchwalow IB,
Végh A, Felszeghy E and Piffkó J: Gains and losses of adhesion
molecules (CD44, E-cadherin, and beta-catenin) during oral
carcinogenesis and tumour progression. J Pathol. 198:343–351. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
38
|
Mancia F and Shapiro L: ADAM and Eph: how
Ephrin-signaling cells become detached. Cell. 123:185–187. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hasegawa-Ishii S, Shimada A, Inaba M, Li
M, Shi M, Kawamura N, Takei S, Chiba Y, Hosokawa M and Ikehara S:
Selective localization of bone marrow-derived ramified cells in the
brain adjacent to the attachments of choroid plexus. Brain Behav
Immun. 29:82–97. 2013. View Article : Google Scholar
|
|
40
|
Gibb DR, Saleem SJ, Chaimowitz NS, Mathews
J and Conrad DH: The emergence of ADAM10 as a regulator of
lymphocyte development and autoimmunity. Mol Immunol. 48:1319–1327.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Schulte M, Reiss K, Lettau M, Maretzky T,
Ludwig A, Hartmann D, de Strooper B, Janssen O and Saftig P: ADAM10
regulates FasL cell surface expression and modulates FasL-induced
cytotoxicity and activation-induced cell death. Cell Death Differ.
14:1040–1049. 2007.PubMed/NCBI
|
|
42
|
Endres K and Fahrenholz F: The role of the
anti-amyloidogenic secretase ADAM10 in shedding the APP-like
proteins. Curr Alzheimer Res. 9:157–164. 2012. View Article : Google Scholar
|
|
43
|
Crawford HC, Dempsey PJ, Brown G, Adam L
and Moss ML: ADAM10 as a therapeutic target for cancer and
inflammation. Curr Pharm Des. 15:2288–2299. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dreymueller D, Uhlig S and Ludwig A:
ADAM-family metalloproteinases in lung inflammation: potential
therapeutic targets. Am J Physiol Lung Cell Mol Physiol.
308:L325–L343. 2015. View Article : Google Scholar
|
|
45
|
Maretzky T, Scholz F, Köten B, Proksch E,
Saftig P and Reiss K: ADAM10-mediated E-cadherin release is
regulated by proinflammatory cytokines and modulates keratinocyte
cohesion in eczematous dermatitis. J Invest Dermatol.
128:1737–1746. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Schirrmeister W, Gnad T, Wex T,
Higashiyama S, Wolke C, Naumann M and Lendeckel U: Ectodomain
shedding of E-cadherin and c-Met is induced by Helicobacter pylori
infection. Exp Cell Res. 315:3500–3508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yoshimura T, Tomita T, Dixon MF, Axon AT,
Robinson PA and Crabtree JE: ADAMs (a disintegrin and
metalloproteinase) messenger RNA expression in Helicobacter
pylori-infected, normal, and neoplastic gastric mucosa. J Infect
Dis. 185:332–340. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
48
|
Balzer EM and Konstantopoulos K:
Intercellular adhesion: mechanisms for growth and metastasis of
epithelial cancers. Wiley Interdiscip Rev Syst Biol Med. 4:171–181.
2012. View Article : Google Scholar
|
